Financial Performance - Q1 FY27 (Standalone)

Revenue Metrics

  • Revenue from Operations: ₹756.3 Cr (Q1 FY26: ₹551.7 Cr) - 37.1% YoY growth
  • Other Income: ₹8.2 Cr (Q1 FY26: ₹7.4 Cr)
  • Total Revenue: ₹764.4 Cr (Q1 FY26: ₹559.1 Cr) - 36.7% YoY growth
  • Quarter-over-Quarter: Revenue increased 22.1% from Q4 FY26 (₹619.5 Cr)

Profitability Metrics

  • EBITDA: ₹111.7 Cr (Q1 FY26: ₹69.5 Cr) - 60.7% YoY growth
  • EBITDA Margin: 14.6% (Q1 FY26: 12.4%)
  • EBIT: ₹90.4 Cr (Q1 FY26: ₹49.8 Cr) - 81.7% YoY growth
  • Profit Before Tax: ₹86.8 Cr (Q1 FY26: ₹45.5 Cr) - 90.5% YoY growth
  • Profit After Tax: ₹64.5 Cr (Q1 FY26: ₹34.0 Cr) - 89.9% YoY growth
  • PAT Margin: 8.4% (Q1 FY26: 6.1%)
  • EPS: ₹2.20 (Q1 FY26: ₹1.16)

Cost Structure

  • Cost of Materials Consumed: ₹506.8 Cr
  • Employee Benefits Expense: ₹71.2 Cr
  • Other Expenses: ₹103.5 Cr
  • Finance Costs: ₹3.6 Cr
  • Depreciation and Amortization: ₹21.3 Cr

Business Overview and Strategic Developments

Expansion Initiatives

  • Purchased 101 acres on Chandigarh-Bathinda Highway for new site development
  • Currently securing clearances for industrial use, environmental compliance, and NHAI approvals

Manufacturing Capacity

  • Total Installed Capacity: 2,13,126 MTPA
  • API Capacity: 30,726 MTPA
  • Specialty Chemicals Capacity: 1,82,400 MTPA
  • Integrated Manufacturing Complex: 180+ acres at single location

Product Portfolio

  • Diversified API platform with backward integration across key products
  • Non-Ibuprofen API segment showing growth with portfolio across multiple therapeutic areas
  • Key products include Paracetamol, Metformin, Clopidogrel, Fenofibrate, and Pantoprazole
  • Non-Ibuprofen share in pharmaceuticals segment increased from 18% to 37% over past six years

Key Manufacturing Capabilities

  • Among largest global manufacturers of Iso Butyl Benzene (IBB) worldwide
  • Ethyl Acetate manufacturing capacity: 1,20,000 MTPA
  • Acetic Anhydride capacity: 32,000 MTPA (major input for Paracetamol)
  • Asia's first continuous dual technology plant for MCA and Acetyl Chloride using green chemistry
  • REACH-certified for Ethyl Acetate & Acetic Anhydride enabling EU exports

Certifications and Accreditations

  • USFDA Approved Facility
  • EUGMP Certification
  • EDQM Certificate of Suitability
  • DMF Registration from MFDS Korea
  • ANVISA, Brazil approval
  • CDE of NMPA, China approval
  • GMP Certificate by Russian Federation
  • WHOGMP (COPP) Certified
  • ISO 9001:2015, 14001:2015 & 45001:2018
  • ISO 27001 & ISO 37001
  • Ecovadis Gold Medal Recipient (ranked among top 5% of companies assessed globally for ESG performance)

Research & Development

  • 120-member team including 50+ scientists
  • DSIR approved facility for research & development
  • Working on generic molecules with latest equipment & techniques
  • In-house development of multi-step products

Leadership Team

  • Varinder Gupta: Managing Director (38+ years experience)
  • Vikas Gupta: Joint Managing Director (B.Sc. (Hons.) in Business Management from Kings College, London)
  • Abhiraj Gupta: Executive Director (oversees non-Ibuprofen API and chemical business, R&D, regulatory, and digital marketing)
  • Kushal Kumar Rana: Director – Works (33+ years experience, Master's in Chemistry, SLDP from IIM Bangalore)

Board of Directors

  • Rajender Mohan Malla: Chairman and Independent Director (Commerce background, 4 decades in banking/financial institutions)
  • Sharad Tyagi: Independent Director (Engineering from Delhi University, MBA from IIM Ahmedabad, 38+ years entrepreneurial experience)
  • Harpal Singh: Independent Director (Chartered Engineer, 37+ years in banking and financial services, former General Manager of Punjab National Bank)
  • Ms Rajni Jha: Independent Director (M.Sc. in Synthetic Organic Chemistry, 33+ years in Pharmaceutical Regulatory Affairs, Quality, and Compliance)

CSR Initiatives

  • Total CSR investment during FY26: ₹4.65 Cr
  • Approximately 5.5 lakh lives impacted
  • Healthcare initiatives: ₹2.79 crore invested
  • Social upliftment initiatives: ₹1.40 crore invested
  • Education initiatives: ₹47 lakh invested

Historical Financial Performance (Standalone)

FY26 Annual Performance

  • Revenue from Operations: ₹2,319.1 Cr
  • EBITDA: ₹290.4 Cr (EBITDA Margin: 12.4%)
  • PAT: ₹137.7 Cr (PAT Margin: 5.9%)
  • EPS: ₹4.69

Balance Sheet (as of Mar 26)

  • Total Assets: ₹2,586.7 Cr
  • Property, plant and equipment: ₹1,165.1 Cr
  • Capital Work in progress: ₹93.6 Cr
  • Inventories: ₹371.1 Cr
  • Trade receivables: ₹603.1 Cr
  • Cash and cash equivalents: ₹65.3 Cr
  • Total Equity: ₹1,798.4 Cr
  • Borrowings: ₹132.0 Cr (current liabilities)

Industry Overview and Growth Drivers

  • China+1 supply chain shift benefiting Indian API manufacturers
  • Shift towards high-value APIs and specialty segments
  • Patent expirations through 2030 creating opportunities
  • Rising demand from regulated markets supporting export growth
  • PLI schemes and KSM self-reliance initiatives
  • Chronic disease demand driving sustained API demand

Forward Guidance for FY26-27

  • Revenue Growth: 15%-20%
  • EBITDA Margin: 14%-15%
  • Exports Contribution: 25%-30%
  • Capex: ₹200-250 Crs

Investor Relations Contacts

  • Mr. Abhay Raj Singh - Sr. VP & Company Secretary
  • Investor Relations Advisors: MUFG Intime India Private Limited